Abstract
Aldehydes are ubiquitous intermediates in metabolic pathways, and their innate reactivity can often make them quite unstable. There are several aldehydic intermediates in the metabolic pathway for tryptophan degradation which can decay into neuroactive compounds that have been associated with numerous neurological diseases, such as quinolinic acid (QUIN). An enzyme of this pathway, 2-aminomuconate-6-semialdehyde dehydrogenase, which is responsible for ‘disarming’ the final aldehydic intermediate, has yet to be studied at the molecular level. Its activity steers the vast majority of metabolic flux to further catabolism and prevents overproduction of a metabolic dead-end, picolinic acid. In this presentation we will show the crystal structures of a bacterial analogue enzyme in five catalytically relevant forms, two of which are covalently-bound, substrate-enzyme adducts. The crystal- and solution-state spectroscopic data along with the crystal structures also reveal that the substrate must undergo an isomerization reaction prior to oxidation. This study provides an in-depth mechanistic understanding of an anticipated dehydrogenase in the kynurenine pathway.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.